disease activity

Benefits of long-term Tysabri seen in RRMS patients in Japan: Study

Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…

More Inflammation Biomarkers in Spinal Fluid of PPMS Patients: Study

Individuals with primary progressive multiple sclerosis (PPMS) have significantly higher concentrations of specific inflammation biomarkers in their spinal fluid than healthy people, an exploratory study shows. For most biomarkers, levels in PPMS patients were comparable to or lower than those seen in people with relapsing-remitting multiple sclerosis (RRMS).

New Blood Biomarker Technology May Help to Predict MS Activity

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…

Combo of Biomarkers Predict Future Disease Activity

In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. ā€œOur findings encourage the application of both sNfL and retinal…

#ACTRIMS2021 – Benign Versus Aggressive MS ā€“ the Hunt for Clues

Editorā€™s note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25ā€“27. GoĀ hereĀ to see the latest stories from the conference. While researchers make progress in pinpointing markers of disease progression in multiple sclerosis (MS), identifying those that signal…

Rituximab Effects Evident at Low Dose, Persist After Treatment Stops

Rituximab shows long-term benefits, even among people with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) who stopped its use or reduced their dose, a study reported. Researchers found little evidence of disease reactivation among patients who discontinued the medication, and an adequate inflammatory disease suppression…

Stem Cell Transplant Reduces Relapses and Disability in RRMS, Study Suggests

Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a small study suggests. The study, ā€œSelective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation…